Ovarian Cancer Canada

Western Regional Blog – BC, YK, AB, NWT and Nunavut

Hot Cancer Cells Are Easier To Kill: New Drug Delivery System Uses Nanotechnology Heating To Kill 95 Percent Of Ovarian Cancer Cells

Oregon State University researchers have found that using nanotechnology with heat and cytotoxic drugs can kill up to 95% of ovarian cancer cells. While there is still additional research that needs … Continue reading

November 19, 2013

Update: Supply Interruption of DOXIL® (doxorubicin HCl liposome injection)

Johnson & Johnson has announced that it is likely the Doxil shortage will continue through the end of 2014. They announced that their main supplier of Doxil has decided to close … Continue reading

November 19, 2013

Female Hormones Key to Breast and Ovarian Cancer in BRCA Gene Carriers

A new study released in Lancet Oncology showed that abnormal levels of female hormones in the bloodstream may be why women with BRCA1 or BRCA2 mutations are at a higher risk … Continue reading

November 19, 2013

Screening for HPV May Be Better Than Pap Test, Study Suggests

Screening offered greater protection against cervical cancer three years after either test was given. By Robert Preidt http://www.nlm.nih.gov/medlineplus/news/fullstory_142167.html SATURDAY, Nov. 2 (HealthDay News) — Screening for the human papillomavirus (HPV) … Continue reading

November 19, 2013

PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer

Vintafolide binds to the folate receptor, a molecule that is expressed on the majority of ovarian cancers. When added to pegylated liposomal doxorubicin in this 149-patient trial, it improved median progression-free survival … Continue reading

November 19, 2013

Ontario Tumour Bank to Supply Samples to COEUR, a Pan-Canadian Ovarian Cancer Research Project

“The Ontario Tumour Bank (OTB) will supply ovarian tumour samples to the Canadian Ovarian Cancer Experimental Unified Resource (COEUR) in an effort to further enhance ovarian cancer research in Canada…” Canada NewsWire … Continue reading

November 19, 2013

Sleep Disturbances in Cancer Patients: Under Recognized and Under Treated

“Managing insomnia involves both pharmacologic and nonpharmacologic treatment. It is also important to treat the associated disorders such as depression and anxiety disorders that often accompany insomnia. Long-term management of cancer patients … Continue reading

November 19, 2013

TRINOVA-1 Signals New Direction in Ovarian Cancer

“Adding the investigational peptibody trebananib to weekly paclitaxel prolongs the time to disease progression or death in women with recurrent, advanced ovarian cancer, the phase III TRINOVA-1 trial has shown.” IMNG Medical … Continue reading

November 19, 2013

Secular, Spiritual, and Religious Existential Concerns of Women with Ovarian Cancer during Final Diagnostics and Start of Treatment

“Hope and courage to face life represent significant personal resources that are created not only in the interplay between body and mind but also between patients and their healthcare professionals. The overall … Continue reading

November 19, 2013

Complementary and Alternative Therapies

CAMEO

Research in BC

The Injustices of Ovarian Cancer

Ovarian Cancer Canada